Cholesterol, statins, and dementia: What the cardiologist should know

Clinical Cardiology

Volumn 38, Issue 4, 2015, Pages 243-250

  Wanamaker, Brett L ^a   Swiger, Kristopher J ^a   Blumenthal, Roger S ^a   Martin, Seth S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; DONEPEZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CARDIOLOGIST; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITION; DEMENTIA; DYSLIPIDEMIA; HUMAN; NONHUMAN; PRIMARY PREVENTION; REVIEW; BLOOD; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPLICATION; DYSLIPIDEMIAS; RISK;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COMORBIDITY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK;

EID: 84928434453     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22361     Document Type: Review

References (71)

1. Thies W, Bleiler L,; Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013; 9: 208-245.
2. Newman AB, Fitzpatrick AL, Lopez O, et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc. 2005; 53: 1101-1107.
3. Fonseca AC, Resende R, Oliveira CR, et al. Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol. 2010; 223: 282-293.
4. Top US pharmaceutical products by spending, 2012. IMS Health Inc. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/Top-line-data/Top-Products-by-RX.pdf. Last updated February 23, 2012. Accessed January 26, 2014.
5. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;129(25 suppl 2):S46-S48]. Circulation. 2014; 129 (25 suppl 2): S1-S45.
6. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia [published correction appears in Lancet. 2001;357:562]. Lancet. 2000; 356: 1627-1631.
7. McGeer PL, McGeer EG,. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013; 126: 479-497.
8. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002; 137: 149-155.
9. Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009; 28: 75-80.
10. Matsuzaki T, Sasaki K, Hata J, et al. Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study. Neurology. 2011; 77: 1068-1075.
11. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003; 61: 199-205.
12. Wood WG, Li L, Müller WE, et al. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem. 2014; 129: 559-572.
13. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261: 921-923.
14. Silva T, Teixeira J, Remião F, et al. Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways. Angew Chem Int Ed Engl. 2013; 52: 1110-1121.
15. Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci U S A. 2001; 98: 5815-5820.
16. Hirsch-Reinshagen V, Burgess BL, Wellington CL,. Why lipids are important for Alzheimer disease? Mol Cell Biochem. 2009; 326: 121-129.
17. Stewart R, White LR, Xue QL, et al. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2007; 64: 103-107.
18. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005; 62: 1556-1560.
19. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2000; 21: 49-55.
20. Gottesman RF, Schneider AL, Albert M, et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk In Communities neurocognitive study. JAMA Neurol. 2014; 71: 1218-1227.
21. Rusanen M, Kivipelto M, Quesenberry CP Jr, et al. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med. 2011; 171: 333-339.
22. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010; 75: 1195-1202.
23. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology. 2011; 77: 1126-1134.
24. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007; 69: 1850-1858.
25. Gharacholou SM, Reid KJ, Arnold SV, et al. Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status Registry. Am Heart J. 2011; 162: 860.e1-869.e1.
26. Kalaria RN, Ballard C,. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999; 13 (suppl 3): S115-S123.
27. Mathias JL, Burke J,. Cognitive functioning in Alzheimer's and vascular dementia: a meta-analysis. Neuropsychology. 2009; 23: 411-423.
28. Zamrini E, McGwin G, Roseman JM,. Association between statin use and Alzheimer's disease. Neuroepidemiology. 2004; 23: 94-98.
29. Hajjar I, Schumpert J, Hirth V, et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002; 57: M414-M418.
30. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002; 59: 223-227.
31. Rodriguez EG, Dodge HH, Birzescu MA, et al. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002; 50: 1852-1856.
32. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam study. J Neurol Neurosurg Psychiatry. 2009; 80: 13-17.
33. Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc. 2010; 58: 1311-1317.
34. Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory study. J Stroke Cerebrovasc Dis. 2012; 21: 436-444.
35. Sparks DL, Kryscio RJ, Sabbagh MN, et al. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008; 5: 416-421.
36. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health. 2011; 65: 949-957.
37. Cramer C, Haan MN, Galea S, et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008; 71: 344-350.
38. Ancelin ML, Carrière I, Barberger-Gateau P, et al. Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis. 2012; 30: 629-637.
39. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005; 62: 1047-1051.
40. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008; 70 (19 part 2): 1795-1802.
41. Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009; 67: 99-109.
42. Song Y, Nie H, Xu Y, et al. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int. 2013; 13: 817-824.
43. Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013; 88: 1213-1221.
44. Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013; 159: 688-697.
45. Urano Y, Hayashi I, Isoo N, et al. Association of active γ-secretase complex with lipid rafts. J Lipid Res. 2005; 46: 904-912.
46. Shinohara M, Sato N, Kurinami H, et al. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J Biol Chem. 2010; 285: 22091-22102.
47. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007; 69: 878-885.
48. Zhang YY, Fan YC, Wang M, et al. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease. Clin Interv Aging. 2013; 8: 103-110.
49. Barone E, Cenini G, Di Domenico F, et al. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res. 2011; 63: 172-180.
50. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129-1135.
51. Hughes TM, Kuller LH, Barinas-Mitchell EJ, et al. Arterial stiffness and β-amyloid progression in nondemented elderly adults. JAMA Neurol. 2014; 71: 562-568.
52. Martins IJ, Berger T, Sharman MJ, et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem. 2009; 111: 1275-1308.
53. US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/drugs/drugsafety/ucm293101.htm. Updated July 2012. Accessed January 26, 2014.
54. Evans MA, Golomb BA,. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009; 29: 800-811.
55. Blom DJ, Wasserman SM, Stein EA,. Evolocumab in hyperlipidemia. N Engl J Med. 2014; 371: 877-878.
56. Robinson JG, Nedergaard BS, Rogers WJ, et al. LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014; 311: 1870-1882.
57. Rosen WG, Mohs RC, Davis KL,. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141: 1356-1364.
58. Sparks DL, Connor DJ, Sabbagh MN, et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006; 185: 3-7.
59. Oremus M., Does the evidence say a 4-point change in ADAS-Cog score is clinically significant? Alzheimers Dement. 2014; 10: 416-417.
60. Feldman HH, Doody RS, Kivipelto M, et al. LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010; 74: 956-964.
61. Jones RW, Kivipelto M, Feldman H, et al. LEADe Investigators. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008; 4: 145-153.
62. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011; 77: 556-563.
63. Rosenblum WI,. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging. 2014; 35: 969-974.
64. Charité University, German Federal Ministry of Education and Research. Trial of simvastatin in amnestic mild cognitive impairment (MCI) patients (SIMaMCI). http://clinicaltrials.gov/show/NCT00842920. Accessed August 15, 2014.
65. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
66. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360: 1623-1630.
67. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly: results of the PROSPER study. J Neurol. 2010; 257: 85-90.
68. Riekse RG, Li G, Petrie EC, et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis. 2006; 10: 399-406.
69. Carlsson CM, Gleason CE, Hess TM, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis. 2008; 13: 187-197.
70. Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013; 80: 1888-1894.
71. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;63(25 part B):3026]. J Am Coll Cardiol. 2014; 63 (25 part B): 2935-2959.